Literature DB >> 7955843

Directional atherectomy in the treatment of anastomotic neointimal hyperplasia associated with prosthetic arterial grafts: technique and preliminary results.

S J Vinnicombe1, S D Heenan, A M Belli, T M Buckenham.   

Abstract

The development of anastomotic neointimal hyperplasia is a common cause of late prosthetic arterial bypass graft failure. The cost and morbidity of graft failure are high, hence the widespread use of graft surveillance programmes in order to detect graft-related stenoses before they progress to occlusion. However, the optimal treatment of stenoses secondary to neointimal hyperplasia is not clear, with a number of authors reporting poor results with both balloon angioplasty and surgical revision. We report our early experience with the Simpson atherectomy catheter in the treatment of anastomotic neointimal hyperplasia associated with prosthetic arterial grafts at eight sites in seven patients. A high technical success rate may be expected and further long-term studies of this mode of treatment are indicated.

Entities:  

Mesh:

Year:  1994        PMID: 7955843     DOI: 10.1016/s0009-9260(05)81965-8

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Evaluation and complications of direct graft puncture in thrombolysis and other interventional techniques.

Authors:  M G Cowling; A M Belli; T M Buckenham
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Mar-Apr       Impact factor: 2.740

2.  Evaluation of the pullback atherectomy catheter in the treatment of lower limb vascular disease.

Authors:  S Grubnic; S D Heenan; T M Buckenham; A M Belli
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

3.  Treatment of anastomotic stenoses of peripheral bypass grafts with cutting balloon angioplasty.

Authors:  A Basile; D Tsetis; G Chlouverakis; G Calcara; G Ardita; G Giulietti; M Di Salvo; A Granata; T Lupattelli; M T Patti
Journal:  Radiol Med       Date:  2008-06-03       Impact factor: 3.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.